Company / Current Assets
ArriVent BioPharma, Inc. Current Assets History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$227.0M
FY2024
5-year range
$160.0M / $227.0M
FY2023-FY2024
Trend
+41.9%
vs FY2023
Sector context
#185 of 213
Health Care
What the data says
ArriVent BioPharma, Inc.'s current assets of $227M is lower than 87% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$227M in FY2024.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 213This company $227.0M Sector average $2.5B
▼
-91.0% below sector average
Key checks
Key Insights
- In FY2024, current assets increased 41.9% year-over-year.
- Ranks #185 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $227.0M | +41.9% |
| FY2023 | $160.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026